DFDA

Famotidine (H2-Receptor Antagonist)

Treatment for Peptic Ulcer Disease

Typical Dosage: 20-40mg once or twice daily

Effectiveness
70%
Safety Score
80%
Clinical Trials
4
Participants
100K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
20-40mg once or twice daily
Time to Effect
1-2 weeks for symptom relief, 6-8 weeks for healing
Treatment Duration
6-8 weeks for acute, often longer for maintenance
Evidence Quality
HIGH
Number Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$100
Side Effect Mgmt:$10
Total Annual:$140
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$8,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$200
Cost per Remission
$233.33
Famotidine (H2-Receptor Antagonist) Outcomes

for Peptic Ulcer Disease

Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+70%
Remission Rate
+60%
Common Side Effects
Headache
+3%
Dizziness
+1%
Nausea
+1%

Sources:

droracle.ai
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
4 completed trials for Famotidine (H2-Receptor Antagonist) in Peptic Ulcer Disease

Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

NCT02418312COMPLETEDNA
View Study
228 participants
INTERVENTIONAL
Kaohsiung City, Taiwan
Started: Jan 1, 2012

Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

NCT02551744COMPLETEDNA
View Study
101 participants
INTERVENTIONAL
Kaohsiung City, Taiwan
Started: Jul 1, 2012

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

NCT00229424COMPLETEDPHASE3
View Study
325 participants
INTERVENTIONAL
1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan
Started: Apr 1, 2005

Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

NCT03667703COMPLETEDPHASE4
View Study
70 participants
INTERVENTIONAL
Boston, United States
Started: Mar 10, 2019